Which patients with primary, early-stage NSCLC would you utilize immunotherapy in conjunction with SBRT?

The trial from Chang et al., PMID 37478883 testing SBRT +/- IO for early-stage NSCLC was a randomized phase II trial. Although very exciting results, it's not a phase III trial and does not technically change management. IO agents are not FDA-approved in this setting yet! There are at least 2 phase III trials asking this question. RTOG 3515/PAC 4 is a 650-patient trial. Only 10 patients are left to meet accrual! The arms are SBRT followed by IO versus placebo. SWOG/NRG S1914 is also a phase III randomized trial testing up front IO followed by SBRT vs SBRT alone. This trial does not require placebo. It is also accruing well. Both were designed together and will test strategies of up front IO versus IO following SBRT dosing in lung cancer. Si...